UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
|
of incorporation) |
|
File Number) |
|
Identification No.) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Address of principal executive offices) |
|
|
|
(Zip Code) |
(Registrant’s telephone number, including area code): (
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: |
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 9, 2021, Beam Therapeutics Inc. (the “Company”) held its 2021 annual meeting of stockholders (the “Annual Meeting”). The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 23, 2021.
Proposal 1 — The following nominees were elected as Class I directors to serve on the Company’s board of directors until the Company’s 2024 annual meeting of stockholders, and until their respective successors have been duly elected and qualified, based on the following votes:
|
Nominee |
|
For |
|
|
Against |
|
|
Abstentions |
|
|
Broker Non-Votes |
|
||||
|
Kristina Burow |
|
|
31,570,398 |
|
|
|
6,874,549 |
|
|
|
8,883 |
|
|
|
7,170,395 |
|
|
Graham Cooper |
|
|
34,139,249 |
|
|
|
4,304,023 |
|
|
|
10,558 |
|
|
|
7,170,395 |
|
Proposal 2 — The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2021 was ratified, based on the following votes:
|
For |
|
|
Against |
|
|
Abstentions |
|
|
Broker Non-Votes |
|
||||
|
|
45,478,127 |
|
|
|
35,783 |
|
|
|
110,315 |
|
|
|
- |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
BEAM THERAPEUTICS INC. |
|
|
|
|
|
|
|
Date: June 11, 2021 |
|
By: |
/s/ John Evans |
|
|
|
|
John Evans |
|
|
|
|
Chief Executive Officer |